XML 30 R23.htm IDEA: XBRL DOCUMENT v3.19.3
The Company and Summary of Significant Accounting Policies - Additional Information (Detail)
3 Months Ended
Sep. 30, 2019
USD ($)
ClinicalTrials
Jun. 30, 2019
USD ($)
Targeted or Tracking Stock, Stock [Line Items]    
Number of clinical stage candidates | ClinicalTrials 4  
Number of candidate in an ongoing global registration trial | ClinicalTrials 1  
Unrecognized tax benefits   $ 0
Accumulated Losses Since Inception $ (234,212,000) $ (231,218,000)
Cash And Cash Equivalents,Short Term Investments And Common Stock Proceeds Receivable $ 65,900,000